NeuroSense Completes Successful Phase IIa and Receives Patent Allowance

NeuroSense Therapeutics has successfully completed a phase IIa…
03/03/2021/by avital

NeuroSense Granted European Orphan Drug Designation

NeuroSense Therapeutics has gained orphan drug designation for…
12/01/2021/by avital

NeuroSense’s Origins, Current Status and Plans Forward

NeuroSense co-founder and CEO Alon Ben-Noon was inspired to find…
07/01/2021/by avital

NeuroSense Presents at ALS/MND Symposium

NeuroSense’s groundbreaking treatment, PrimeC, aims to regulate…
10/12/2020/by avital

Continuation of Positive Trends in ALS Clinical Trial

NeuroSense Therapeutics has reported promising results from their…
18/11/2020/by avital

NeuroSense’s Clinical Trial Interim Results Webinar

Hear the people of NeuroSense discuss the science behind our…
30/09/2020/by avital

Introducing the Women Behind NeuroSense

Avital Pushett is the head of the ALS clinical program at NeuroSense.…
24/09/2020/by avital

Encouraging Interim Results of NeuroSense’s Clinical Study

The interim results from PrimeC’s NST002 clinical trial indicated…
09/09/2020/by avital

Clinical Studies Initiation and Orphan Drug Designation

PrimeC, developed by NeuroSense Therapeutics, has received an…
12/02/2020/by avital
Ariel Gordon and Yossi Gross founded NeuroSense

Meet our Investors

The prospect of a viable treatment for ALS has inspired serial…
25/03/2019/by tasik

Read NeuroSense’s Story

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative…
10/02/2019/by tasik

Zebrafish Assist in the Battle Against ALS

Dr. Niva Russek-Blum is a neurobiologist and senior researcher…
03/01/2019/by tasik